Search
Ripasudil
go.drugbank.com/drugs/DB13165InvestigationalRipasudil, as hydrochloride hydrate (K-115), is a specifc Rho-associated coiled-coil containing protein kinase (ROCK) inhibitor used for the treatment of glaucoma and ocular hypertension.
Topiroxostat
go.drugbank.com/drugs/DB01685InvestigationalRenal complications are major comorbidities that limit the [DB00437] therapy as dose reductions are recommended. … Xanthine oxidase inhibitors are classified into two groups; purine analogs such as [DB00437] and [DB05262], and non-purine agents which includes topiroxostat.
Cystine
go.drugbank.com/drugs/DB00138ApprovedInvestigationalNutraceuticalWithdrawnA covalently linked dimeric nonessential amino acid formed by the oxidation of cysteine. Two molecules of cysteine are joined together by a disulfide bridge to form cystine.
Aminomethylbenzoic acid
go.drugbank.com/drugs/DB13244ExperimentalAminomethylbenzoic acid may be useful as an antifibrinolytic agent [A174994].
AMG 108
go.drugbank.com/drugs/DB05545InvestigationalAMG 108 was investigated for use as an antirheumatic agent.
Hexobarbital
go.drugbank.com/drugs/DB01355ExperimentalA barbiturate that is effective as a hypnotic and sedative.
Canakinumab
go.drugbank.com/drugs/DB06168ApprovedInvestigationalwell as for patients 2 years of age and older to treat systemic juvenile idiopathic arthritis (SJIA). … for patients 4 years of age and older to treat Familial Cold Autoinflammatory Syndrome (FCAS) and Muckle-Wells Syndrome (MWS), which are both part of the Cryopyrin-Associated Periodic Syndromes (CAPS) as
Difelikefalin
go.drugbank.com/drugs/DB11938ApprovedInvestigational[A237610] These revelations led to the study of KOR agonists as a potential treatment option in patients suffering from pruritic conditions. … [A237615,A237620] The clinical burden of uremic pruritus in this patient population is being increasingly recognized as contributing to a significant reduction in patient quality of life, poor outcomes
Telotristat ethyl
go.drugbank.com/drugs/DB12095ApprovedTelotristat ethyl is a prodrug of telotristat that was approved by the FDA in March 2017 as Xermelo. … [L43342] It was previously referred to as telotristat etiprate, the hippurate salt form; however, the FDA recommends the use of the name of the neutral form rather than that of the salt.